Image

Breaking News

Featured image for “SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma”
10/22/2025

SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma

Rotterdam, The Netherlands – San Diego, CA – [October 22nd] – SkylineDx today announced that results from its landmark MERLIN_001…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma”
10/20/2025

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026   WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) — Replimune…
Blog - Melanoma360
, 
Breaking News
Featured image for “Remembering Brandon Blackstock: A Call to Action on Melanoma Awareness”
08/12/2025

Remembering Brandon Blackstock: A Call to Action on Melanoma Awareness

Difficult News and A Reminder of the Impact of Melanoma Today we would like to acknowledge the recent death of…
Blog - Melanoma360
, 
Breaking News
Featured image for “IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma”
08/11/2025

IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “The FDA Said No — Now We Need Your Voice”
07/25/2025

The FDA Said No — Now We Need Your Voice

Dear Friends, A recent FDA decision denied approval of a promising new treatment called RP1 for advanced melanoma—one that showed…
Blog - Melanoma360
, 
Breaking News
, 
President's Letter
Featured image for “Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications”
05/28/2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

News provided byHalozyme Therapeutics, Inc. May 28, 2025, 08:30 ET Opdivo® is the first and only PD-1 inhibitor approved for subcutaneous (SC)…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Replimune Announces BLA Acceptance and Priority Review for RP1 for the Treatment in Advanced Melanoma”
01/21/2025

Replimune Announces BLA Acceptance and Priority Review for RP1 for the Treatment in Advanced Melanoma

PDUFA action date of July 22, 2025, with priority review January 21, 2025 08:00 ET| Source: Replimune Group Inc WOBURN,…
Blog - Melanoma360
, 
Breaking News
Featured image for “Jimmy Carter: A Life that Shaped Cancer Treatment and Hope for Melanoma Patients”
12/30/2024

Jimmy Carter: A Life that Shaped Cancer Treatment and Hope for Melanoma Patients

Former U.S. President Jimmy Carter, who passed away on December 29, 2024, at the age of 100, will be remembered…
Blog - Melanoma360
, 
Breaking News
Featured image for “Bristol Myers Squibb Announces Approval for Subcutaneous Nivolumab”
12/27/2024

Bristol Myers Squibb Announces Approval for Subcutaneous Nivolumab

The Food and Drug Administration approval provides another option for cancer patients December 27, 2024 (Sacramento, California) The FDA has…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Replimune Receives Breakthrough Therapy Designation for RP1 and Submits BLA to FDA”
11/22/2024

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits BLA to FDA

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval…
Blog - Melanoma360
, 
Breaking News
10/22/2025

SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma

Rotterdam, The Netherlands – San Diego, CA – [October 22nd] – SkylineDx today announced that results from its landmark MERLIN_001…
Featured image for “SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
10/20/2025

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026   WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) — Replimune…
Featured image for “Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
08/12/2025

Remembering Brandon Blackstock: A Call to Action on Melanoma Awareness

Difficult News and A Reminder of the Impact of Melanoma Today we would like to acknowledge the recent death of…
Featured image for “Remembering Brandon Blackstock: A Call to Action on Melanoma Awareness”
Blog - Melanoma360
 | 
Breaking News
08/11/2025

IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase…
Featured image for “IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
07/25/2025

The FDA Said No — Now We Need Your Voice

Dear Friends, A recent FDA decision denied approval of a promising new treatment called RP1 for advanced melanoma—one that showed…
Featured image for “The FDA Said No — Now We Need Your Voice”
Blog - Melanoma360
 | 
Breaking News
 | 
President's Letter
05/28/2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

News provided byHalozyme Therapeutics, Inc. May 28, 2025, 08:30 ET Opdivo® is the first and only PD-1 inhibitor approved for subcutaneous (SC)…
Featured image for “Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
01/21/2025

Replimune Announces BLA Acceptance and Priority Review for RP1 for the Treatment in Advanced Melanoma

PDUFA action date of July 22, 2025, with priority review January 21, 2025 08:00 ET| Source: Replimune Group Inc WOBURN,…
Featured image for “Replimune Announces BLA Acceptance and Priority Review for RP1 for the Treatment in Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
12/30/2024

Jimmy Carter: A Life that Shaped Cancer Treatment and Hope for Melanoma Patients

Former U.S. President Jimmy Carter, who passed away on December 29, 2024, at the age of 100, will be remembered…
Featured image for “Jimmy Carter: A Life that Shaped Cancer Treatment and Hope for Melanoma Patients”
Blog - Melanoma360
 | 
Breaking News
12/27/2024

Bristol Myers Squibb Announces Approval for Subcutaneous Nivolumab

The Food and Drug Administration approval provides another option for cancer patients December 27, 2024 (Sacramento, California) The FDA has…
Featured image for “Bristol Myers Squibb Announces Approval for Subcutaneous Nivolumab”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
11/22/2024

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits BLA to FDA

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval…
Featured image for “Replimune Receives Breakthrough Therapy Designation for RP1 and Submits BLA to FDA”
Blog - Melanoma360
 | 
Breaking News

Recent Posts

Featured image for “SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma”
Oct. 22, 2025

SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma

Featured image for “Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma”
Oct. 20, 2025

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Featured image for “The Power of Peer Support in Melanoma Survivorship”
Oct. 14, 2025

The Power of Peer Support in Melanoma Survivorship

Featured image for “You’re Not Out of Options—What To Do After First Line Therapy Fails”
Oct. 07, 2025

You’re Not Out of Options—What To Do After First Line Therapy Fails

Featured image for “Caring Through Loss: A Conversation on Bereavement”
Sep. 09, 2025

Caring Through Loss: A Conversation on Bereavement

Filter by Tag